Robert Desnick
Clinical Genetics (M.D.) · New York, NYNPI 1861460859
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 58.7% of the total. Reporting peaked in 2019 at $58,237 and has fallen 99.7% since, to $200 in 2025. Among clinical genetics (m.d.) clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $2993.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$121K
- Mitsubishi Tanabe Pharma Development America, Inc.$50K
- Alnylam Pharmaceuticals Inc.$11K
- Sanofi$8K
- Recordati_rare_diseases_inc.$7K
- Tanabe Pharma America, Inc.$6K
- plus $2K from 3 others
Across 2 payments — averaging $127,302 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$255K
What the payments were for
- Consulting fees$75,27536%
- Speaking & faculty fees$93,02545%
- Travel & lodging$35,66017%
- Food & beverage$2,5941%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 20 | $121,310 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 17 | $50,469 |
| Alnylam Pharmaceuticals Inc. | 10 | $11,275 |
| Sanofi | 6 | $8,208 |
| Recordati_rare_diseases_inc. | 5 | $7,245 |
| Tanabe Pharma America, Inc. | 5 | $6,153 |
| Sanofi US Services Inc. | 1 | $1,500 |
| EUSA Pharma (US) LLC | 4 | $343 |
| AstraZeneca | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$122,196
- GIVLARRI$6,400
- GIVLAARI$4,125
- PANHEMATIN$3,000
- Carbaglu$328
How this compares
$206,554 in reported general payments places this provider in the 95th percentile of 49 clinical genetics (m.d.) providers in New York.
Other clinical genetics (m.d.) in New York
- Manisha BalwaniNew York$188K
- Jaya GaneshNew York$65K
- George DiazNew York$44K
- Christopher CunniffNew York$25K
- David BeckNew York$21K
- Kimihiko OishiNew York$15K
- Mary LopiccoloNew York$13K
- Noura Abul HusnNew York$6K
- Ronald WapnerNew York$5K
- Laura PisaniNew York$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.